Loading...

Bristol-Myers Squibb Company Ce

CELG-RI•NYSE
HealthcareDrug Manufacturers - General
$0.03
$-0.00(-0.39%)

Bristol-Myers Squibb Company Ce (CELG-RI) AI-Powered Stock Analysis

See how Bristol-Myers Squibb Company Ce scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer

Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overall Grade

Bristol-Myers Squibb Company Ce’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

B+

Good

Grade Breakdown by Metric

See how each financial and market factor contributes to Bristol-Myers Squibb Company Ce's overall stock rating.

Forecast

C+

Score

55/100

Financial Growth

B

Score

65/100

Fundamental Growth

C+

Score

50/100

Key Ratios

A

Score

84/100

Sector Comparison

B+

Score

75/100

Industry Comparison

A+

Score

95/100

S&P 500 Benchmark

A

Score

85/100

Analyst Consensus

C+

Score

50/100

Component Analysis Explained

Understand the key factors behind each Bristol-Myers Squibb Company Ce stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions